Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Syncona Ltd.. (4/30/20). "Press Release: Danny Bar-Zohar Joins Syncona as Partner".

Organisations Organisation Syncona Ltd.
  Group Syncona (Group)
  Organisation 2 Novartis AG (NYSE: NVS)
  Group Novartis (Group)
Products Product venture capital
Persons Person Bar-Zohar, Danny (Syncona 202004– Partner before Novartis + Teva + Tel-Aviv Sourasky Medical Center)
  Person 2 Murphy, Martin (Syncona CEO before Wellcome Trust Sigma project + MVM Life Science Partners + 3i + McKinsey)

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life sciences, announces the appointment of Danny Bar-Zohar, M.D., as Syncona Partner, from 17 April 2020. In this role, Danny will leverage his expertise in clinical development, regulatory environments and medical affairs to help Syncona further build and establish its portfolio of life science companies.

Danny has almost 15 years of experience in the pharmaceutical and biotechnology sector, having worked at Teva Pharmaceutical Industries and Novartis Pharma after practicing medicine for over a decade. He joins from Novartis where, most recently, he was Global Head of Clinical Development and Analytics, leading all late-stage clinical development across neuroscience, immunology, oncology and ophthalmology, amongst others. During his 7 years at Novartis, Danny held multiple roles including Global Head of Neuroscience Development and Chief Scientific Officer of Novartis Pharma Italy.

Before joining Novartis, Danny spent 7 years at Teva Pharmaceutical industries Global Innovative Products division where he headed multiple therapy areas and clinical programmes in Neurology. Prior to Teva, Danny had practiced general surgery at Tel-Aviv Sourasky Medical Center, having studied medicine at the Sackler Faculty of Medicine, Tel-Aviv University in Israel.

Martin Murphy, Chief Executive of Syncona Investment Management Limited, said: “Danny has a wealth of experience in clinical development and we are excited to welcome him to our team. Having served as a surgeon for over a decade, Danny is acutely aware of medicine’s profound impact and we share his drive to improve patient outcomes through transformative treatments. Furthermore, we were particularly drawn to Danny’s deep understanding of the evidence needed to bring high-value therapeutics to patients as this aligns with Syncona’s commercially-oriented found, build, fund strategy.”

Danny Bar-Zohar, Partner at Syncona Investment Management Limited, added: “Working at Syncona means working hands on throughout the entire journey of clinical development, from nurturing academic science to commercialising life-changing therapies. I very much look forward to embedding myself within the team at Syncona and contributing to their excellent work.”

Record changed: 2020-05-04


Picture [iito] Plain Stupid Simple 650x80px

More documents for Syncona (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] No Content Marketing 650x80px

» top